Phase 2 Studies of Novel JAK1 Inhibitor for HS Show Promise

Results of the two phase 2 studies "establish proof of concept" for the JAK1 inhibitor for the treatment of moderate to severe hidradenitis suppurativa, the investigators concluded.
Medscape Medical News

source https://www.medscape.com/viewarticle/967076?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?